BioSpace News Archive

Ardelyx, Inc. (Nasdaq: ARDX) today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of XPHOZAH (tenapanor) for the control of serum phosphate in adult patients with chronic kidney disease on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy.

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an update of results from the final multiple-dose cohort in the ongoing Phase 1a study of its investigational next-generation, highly potent hepatitis B virus (HBV) core inhibitor, ABI-4334.

HTG Molecular Diagnostics, Inc., a platform-based life science tools and drug discovery company, announced the achievement of three significant drug discovery business milestones in the first quarter of 2023.

ProPhase Labs, Inc. today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 10:30 am PST, 1:30 pm EST.

ViaLase, Inc today announced the online publication of 24-month safety data from the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) performed with the ViaLase technology in Ophthalmology® Science, a journal of the American Academy of Ophthalmology.

Chiesi Global Rare Diseases announced a U.S. Networkwide Sponsorship of BioInnovation Labs, the leading developer and operator of life science coworking spaces with 12 active facilities and a growing network in the U.S. and internationally.

Remote patient monitoring (RPM) solutions leader Tenovi announced today that it is launching its cellular-enabled remote Peak Expiratory Flow Meter (PFM).

Xenon Pharmaceuticals Inc. today announced that the company will present at the 22nd Annual Needham Virtual Healthcare Conference taking place April 17-20, 2023.

Daré Bioscience, Inc. today announced that Climacteric , the official journal of the International Menopause Society, published safety and acceptability results from a Phase 1 clinical trial of DARE-HRT1.